More than 100 people die of prostate cancer every day in the United States. There are 180,000 new cases each year and treatment costs$5 billion. Ar-He knife cryotherapy offers a clinically effective approach. Currently there are more than 400 hospitals in the United States, more than 1,000 doctors carry out the U.S. argon helium knife treatment of prostate cancer, treating tens of thousands of patients each year. U.S. FDA approved argon helium knife treatment of prostate cancer and prostate hyperplasia argon helium knife treatment of prostate cancer into the universal health care (Medicare) U.S. argon helium knife treatment of prostate cancer and prostate hyperplasia clinical features: minimally invasive, painless, fewer complications, healing faster, good efficacy advantages currently more than 400 hospitals in the United States installed the use of U.S. Dr. Derrick and others held in 2005, the 69th AUA Southeastern Section presented a retrospective analysis of 249 patients, 88 of which had a 10-year follow-up record. He demonstrated the effectiveness of argon helium knife in treating prostate cancer: 10-year recurrence-free rate: 74% of patients with PSA <1.0ng/ml, 85% with PSA <2.0ng/ml Urinary incontinence incidence: 10% Fistula incidence: <0.5% Dr. Chinn, et al. presented a retrospective analysis of argon helium knife in the treatment of prostate cancer in 292 patients at the 15th International Prostate Cancer Conference, held in 2005, 49 of which had a record of 10-year follow-up. Dr. Chinn et al. presented a retrospective analysis of 292 patients treated with argon helium knife for prostate cancer at the 15th International Conference on Prostate Cancer in 2005, of which 49 had a 9-year follow-up:?93.8% recurrence free?9 years without recurrence: 88% in the low-risk group, 74% in the intermediate-risk group, and 50% in the high-risk group. For advanced prostate cancer that has lost the chance of radical surgery, argon helium knife can not achieve complete treatment, but it can achieve the purpose of tumor reduction, improve urination, improve the quality of life of patients and prolong the survival time. Benign prostatic hyperplasia (BPH) patients account for 50% of men over 50 and 80% of men over 80 in the United States. Prostatic hyperplasia occurs when prostate tissue grows so large that it obstructs the urethra. The Ar-He knife allows the surgeon to perform targeted ablations in selected areas of the enlarged prostate, which can quickly reduce pain and improve urination and other symptoms in patients with prostate enlargement. The efficacy of Ar-He knife for prostate enlargement is similar to that of surgery, but it is less invasive, can be performed under local anesthesia, with minimal bleeding, mild post-treatment reaction, and almost no effect on the general condition. Therefore, in fact, the use of Ar-He knife in the treatment of prostate enlargement has a wider range of indications than that of traditional open surgery and intracavitary surgery. There is no intraoperative bleeding caused by the argon helium knife itself, and there are no significant changes in blood pressure and heart rate. General activities were possible on the next day after the operation, and all of them resumed voluntary urination after the catheter was removed in 2 to 6 weeks, with no case of urinary incontinence, and the injured tract was healed in 4 to 5d. All the treated cases resumed voluntary urination after catheter removal.